Klingman & Associates LLC Has $1.94 Million Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Klingman & Associates LLC grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 300.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,137 shares of the medical research company's stock after purchasing an additional 2,353 shares during the period. Klingman & Associates LLC's holdings in Thermo Fisher Scientific were worth $1,940,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Signature Resources Capital Management LLC increased its holdings in shares of Thermo Fisher Scientific by 318.2% in the 2nd quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company's stock worth $25,000 after acquiring an additional 35 shares during the period. New Millennium Group LLC acquired a new position in Thermo Fisher Scientific during the 2nd quarter valued at about $29,000. Stephens Consulting LLC increased its stake in Thermo Fisher Scientific by 116.0% during the 2nd quarter. Stephens Consulting LLC now owns 54 shares of the medical research company's stock valued at $30,000 after buying an additional 29 shares during the period. Headlands Technologies LLC acquired a new position in Thermo Fisher Scientific during the 1st quarter valued at about $32,000. Finally, Bank & Trust Co acquired a new position in Thermo Fisher Scientific during the 2nd quarter valued at about $33,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Down 0.7 %

NYSE TMO traded down $4.15 during trading on Friday, reaching $551.74. The company's stock had a trading volume of 1,620,732 shares, compared to its average volume of 1,461,084. The business has a 50-day moving average price of $593.95 and a 200-day moving average price of $583.63. Thermo Fisher Scientific Inc. has a 1-year low of $437.26 and a 1-year high of $627.88. The stock has a market capitalization of $211.04 billion, a PE ratio of 34.59, a PEG ratio of 3.70 and a beta of 0.79. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping the consensus estimate of $5.25 by $0.03. The firm had revenue of $10.60 billion for the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The business's quarterly revenue was up .2% on a year-over-year basis. During the same period in the prior year, the business posted $5.69 earnings per share. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be issued a dividend of $0.39 per share. The ex-dividend date is Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.28%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.78%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on TMO shares. Stephens started coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, October 1st. They set an "overweight" rating and a $680.00 price objective for the company. Robert W. Baird reduced their price objective on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an "outperform" rating for the company in a research report on Thursday, October 24th. Royal Bank of Canada reduced their price objective on shares of Thermo Fisher Scientific from $767.00 to $718.00 and set an "outperform" rating for the company in a research report on Thursday, October 24th. Evercore ISI reduced their price objective on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an "outperform" rating for the company in a research report on Thursday, October 24th. Finally, Raymond James raised their price objective on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an "outperform" rating in a research report on Thursday, July 25th. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $649.33.

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $168,048.00. Following the transaction, the executive vice president now directly owns 16,663 shares in the company, valued at approximately $9,333,946.08. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction on Monday, October 28th. The shares were sold at an average price of $554.29, for a total value of $5,542,900.00. Following the transaction, the chief executive officer now directly owns 121,192 shares in the company, valued at approximately $67,175,513.68. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $168,048.00. Following the completion of the transaction, the executive vice president now owns 16,663 shares in the company, valued at $9,333,946.08. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 28,150 shares of company stock worth $15,676,125. 0.34% of the stock is owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.